Dysregulated microRNAs in the pathogenesis and progression of cervical neoplasm

Cell Cycle

Volumn 11, Issue 15, 2012, Pages 2876-2884

  Cheung, Tak Hong ^a   Man, Kwun Nok Mimi ^a   Yu, Mei Yung ^a   Yim, So Fan ^a   Siu, Nelson S S ^a   Lo, Keith W K ^a   Doran, Graeme ^b   Wong, Raymond R Y ^b   Wang, Vivian W ^c   Smith, David I ^c   Worley, Michael J ^b   Berkowitz, Ross S ^b   Chung, Tony K H ^a   Wong, Yick Fu ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Carcinogenesis; Cervical cancer; Cervical intraepithelial neoplasia; MicroRNA; Signature

Indexed keywords

MICRORNA; MICRORNA 20B; MICRORNA 9; MIR 10A; MIR 193B; MIR 203; MIR 338; MIR 345; MIR 34B; MIR 34C; MIR 424; MIR 512 5P; MIR 518A; RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; MICRODISSECTION; PATHOGENESIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX EPITHELIUM; UTERINE CERVIX TUMOR;

EID: 84864568344     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.21278     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.org/ 10.3322/caac.20107.
2. Hong KCR. Hong Kong Cancer Stat. 2008. Hong Kong Hospital Authority 2010.
3. Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005; 15:563-8; PMID:16099643; http://dx.doi.org/10.1016/j. gde.2005.08.005.
4. Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 2002; 12:735-9; PMID:12007417; http://dx.doi.org/10.1016/S0960-9822(02)00809-6.
5. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005; 65:7065-70; PMID:16103053; http://dx.doi.org/10.1158/0008-5472.CAN-05-1783.
6. Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 2006; 25:2537-45; PMID:16331254; http://dx.doi.org/10.1038/sj.onc.1209283.
7. Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, et al. MicroRNA signatures in human ovarian cancer. Cancer Res 2007; 67:8699-707; PMID:17875710; http://dx.doi.org/10.1158/0008-5472.CAN-07-1936.
8. Lui WO, Pourmand N, Patterson BK, Fire A. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res 2007; 67:6031-43; PMID:17616659; http://dx.doi.org/10.1158/0008-5472.CAN-06-0561.
9. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and downregulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99:15524-9; PMID:12434020; http://dx.doi.org/10.1073/pnas.242606799.
10. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-8; PMID:15944708; http://dx.doi.org/10.1038/nature03702.
11. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001; 98:31-6; PMID:11134512; http://dx.doi.org/10.1073/pnas.011404098.
12. Wong YF, Cheung TH, Tsao GS, Lo KW, Yim SF, Wang VW, et al. Genome-wide gene expression profiling of cervical cancer in Hong Kong women by oligonucleotide microarray. Int J Cancer 2006; 118:2461-9; PMID:16353136; http://dx.doi.org/10.1002/ijc.21660.
13. Zhang B, Kirov SA, Snoddy JR. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 2005; 33(web server issue):W741-8; PMID:15980575; http://dx.doi.org/10.1093/nar/ gki475.
14. Wang S, Wang L, Zhu T, Gao X, Li J, Wu Y, et al. Improvement of tissue preparation for laser capture microdissection: application for cell type-specific miRNA expression profiling in colorectal tumors. BMC Genomics 2010; 11:163; PMID:20219115; http://dx.doi.org/10.1186/1471-2164-11-163.
15. Wei JS, Johansson P, Chen QR, Song YK, Durinck S, Wen X, et al. microRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies. Clin Cancer Res 2009; 15:5560-8; PMID:19706822; http://dx.doi.org/10.1158/1078-0432.CCR-08-3287.
16. Lee JW, Choi CH, Choi JJ, Park YA, Kim SJ, Hwang SY, et al. Altered MicroRNA expression in cervical carcinomas. Clin Cancer Res 2008; 14:2535-42; PMID:18451214; http://dx.doi.org/10.1158/1078-0432.CCR-07-1231.
17. Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS ONE 2008; 3:e2557; PMID:18596939; http://dx.doi.org/10.1371/journal.pone.0002557.
18. Muralidhar B, Goldstein LD, Ng G, Winder DM, Palmer RD, Gooding EL, et al. Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels. J Pathol 2007; 212:368-77; PMID:17471471; http://dx.doi.org/10.1002/path.2179.
19. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12:247-56; PMID:20173740.
20. Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L, et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 2010; 70:367-77; PMID:20028871; http://dx.doi.org/10.1158/0008-5472.CAN-09-1891.
21. Tan HX, Wang Q, Chen LZ, Huang XH, Chen JS, Fu XH, et al. MicroRNA-9 reduces cell invasion and E-cadherin secretion in SK-Hep-1 cell. Med Oncol 2010; 27:654-60; PMID:19572217; http://dx.doi.org/10.1007/s12032-009-9264-2.
22. Liang M, Ueno M, Oomizu S, Arikawa T, Shinonaga R, Zhang S, et al. Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma. J Cancer Res Clin Oncol 2008; 134:899-907; PMID:18264727; http://dx.doi.org/10.1007/s00432-008-0352-z.
23. Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S, et al.; HPV-PathogenISS Study Group. Downregulation of E-cadherin is closely associated with progression of cervical intraepithelial neoplasia (CIN), but not with high-risk human papillomavirus (HPV) or disease outcome in cervical cancer. Eur J Gynaecol Oncol 2006; 27:215-23; PMID:16800245.
24. Lee MY, Chou CY, Tang MJ, Shen MR. Epithelialmesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail upregulation. Clin Cancer Res 2008; 14:4743-50; PMID:18676743; http://dx.doi.org/10.1158/1078-0432.CCR-08-0234.
25. He X, He L, Hannon GJ. The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 2007; 67:11099-101; PMID:18056431; http://dx.doi.org/10.1158/0008-5472.CAN-07-2672.
26. Huibregtse JM, Scheffner M, Howley PM. A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO J 1991; 10:4129-35; PMID:1661671.
27. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75:495-505; PMID:8221889; http://dx.doi.org/10.1016/0092- 8674(93)90384-3.
28. Lechner MS, Laimins LA. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol 1994; 68:4262-73; PMID:8207801.
29. Patel D, Huang SM, Baglia LA, McCance DJ. The E6 protein of human papillomavirus type 16 binds to and inhibits co-activation by CBP and p300. EMBO J 1999; 18:5061-72; PMID:10487758; http://dx.doi.org/10.1093/emboj/18.18.5061.
30. Zimmermann H, Degenkolbe R, Bernard HU, O'Connor MJ. The human papillomavirus type 16 E6 oncoprotein can downregulate p53 activity by targeting the transcriptional coactivator CBP/p300. J Virol 1999; 73:6209-19; PMID:10400710.
31. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol 2009; 11:1487-95; PMID:19935649; http://dx.doi.org/10. 1038/ncb1998.
32. Melar-New M, Laimins LA. Human papillomaviruses modulate expression of microRNA 203 upon epithelial differentiation to control levels of p63 proteins. J Virol 2010; 84:5212-21; PMID:20219920; http://dx.doi.org/10.1128/JVI.00078-10.
33. Yi R, Poy MN, Stoffel M, Fuchs E. A skin microRNA promotes differentiation by repressing 'stemness'. Nature 2008; 452:225-9; PMID:18311128; http://dx.doi.org/10.1038/nature06642.
34. Furuta M, Kozaki KI, Tanaka S, Arii S, Imoto I, Inazawa J. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis 2010; 31:766-76; PMID:19843643; http://dx.doi.org/10.1093/carcin/bgp250.
35. Feber A, Xi L, Luketich JD, Pennathur A, Landreneau RJ, Wu M, et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg 2008; 135:255-60, discussion 260; PMID:18242245; http://dx.doi.org/10.1016/j. jtcvs.2007.08.055.
36. Trink B, Osada M, Ratovitski E, Sidransky D. p63 transcriptional regulation of epithelial integrity and cancer. Cell Cycle 2007; 6:240-5; PMID:17297296; http://dx.doi.org/10.4161/cc.6.3.3803.
37. Candi E, Dinsdale D, Rufini A, Salomoni P, Knight RA, Mueller M, et al. TAp63 and DeltaNp63 in cancer and epidermal development. Cell Cycle 2007; 6:274-85; PMID:17264681; http://dx.doi.org/10.4161/cc.6.3.3797.
38. Wang TY, Chen BF, Yang YC, Chen H, Wang Y, Cviko A, et al. Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Hum Pathol 2001; 32:479-86; PMID:11381365; http://dx.doi.org/10.1053/hupa.2001.24324.
39. Hagman Z, Larne O, Edsjö A, Bjartell A, Ehrnström RA, Ulmert D, et al. miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. Int J Cancer 2010; 127:2768-76; PMID:21351256; http://dx.doi.org/10. 1002/ijc.25269.
40. Antonini D, Russo MT, De Rosa L, Gorrese M, Del Vecchio L, Missero C. Transcriptional repression of miR-34 family contributes to p63-mediated cell cycle progression in epidermal cells. J Invest Dermatol 2010; 130:1249-57; PMID:20090763; http://dx.doi.org/10.1038/jid.2009.438.
41. Sasi N, Hwang M, Jaboin J, Csiki I, Lu B. Regulated cell death pathways: new twists in modulation of BCL2 family function. Mol Cancer Ther 2009; 8:1421-9; PMID:19509269; http://dx.doi.org/10.1158/1535-7163.MCT-08-0895.
42. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 2009; 220:292-6; PMID:19415697; http://dx.doi.org/10.1002/jcp. 21791.
43. Wu S, Huang S, Ding J, Zhao Y, Liang L, Liu T, et al. Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region. Oncogene 2010; 29:2302-8; PMID:20190813; http://dx.doi.org/10.1038/onc. 2010.34.
44. Borgdorff V, Lleonart ME, Bishop CL, Fessart D, Bergin AH, Overhoff MG, et al. Multiple microRNAs rescue from Ras-induced senescence by inhibiting p21(Waf1/Cip1). Oncogene 2010; 29:2262-71; PMID:20101223; http://dx.doi.org/10. 1038/onc.2009.497.